Insulin Technology Achieves a New Breakthrough, Medicilon Helps to Make a New Leap Forward!

Medicilon has currently completed the pharmacokinetic study of common insulin and oral insulin compound preparations of a company in Jiangsu, administered the test product subcutaneously and orally, and measured the blood glucose level of animals with a Roche blood glucose meter; Immunoassay (RIA) was used to measure the concentration of insulin and C-peptide in canine serum, and the concentration of insulin in bile. C-peptide was used to correct the level of endogenous insulin, and the results were in line with expectations.

At the same time, the pharmacokinetic and safety evaluation experiments of fast-acting and intermediate-acting insulins were also carried out, mainly including pharmacokinetics, single-dose acute toxicity, 28-day repeated dosing, preparation safety and other experiments. Pharmacokinetics mainly uses enzyme-linked immunosorbent assay (ELISA) to analyze the total insulin and endogenous insulin in dog plasma after administration; further understand the test substance during the single-administration toxicity experiment, and make adjustments to the dosage and supplementation. The analysis and control of the law of sugar; the identification of true or false aggregation results during the hemolysis test; the grasp of the law of sugar supplementation and how to replace sugar supplementation through food supply during the 28-day repeated administration process, etc. How to rescue low animals, etc., these problems have been overcome one by one.